Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label ascending-dose study of luspatercept in myelodysplastic syndromes
2012-002523-14Phase 2Completed
- Sponsor
- Acceleron Pharma Inc.
- Start
- Aug 2012
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of luspatercept in myelodysplastic syndrome (MDS), sponsored by Acceleron Pharma Inc. Primary endpoint: Modified erythroid response. Started Aug 2012; status: completed.
02
Drugs
luspatercept
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on 2012-002523-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-002523-14.